Physician profile
Jonathan D Hydrick
NPI 1740750462
$1,243.48
in general payments reported to CMS, 2019-2025
14 companies · $437 in 2025
The $437 reported for 2025 was more than what 96% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.34 · 2022: $36.39 · 2023: $209 · 2024: $550 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $244.86 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $244.55 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.90 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $112.56 | 2023-2024 | |
| Qol Medical, LLC | $106.50 | 2025 | Sucraid |
| Lilly USA, LLC | $77.82 | 2024 | Omvoh, Zepbound |
| Janssen Biotech, INC. | $72.57 | 2024 | Tremfya, Stelara |
| Merck Sharp & Dohme LLC | $72.12 | 2021-2024 | Dificid, Bridion |
| Madrigal Pharmaceuticals | $42.97 | 2025 | Rezdiffra |
| Edwards Lifesciences Corporation | $36.39 | 2022 | |
| Sandoz INC. | $23.16 | 2024 | Hyrimoz |
| Braintree Laboratories, INC. | $16.33 | 2023 | Suflave |
| Aimmune Therapeutics, INC. | $14.04 | 2024 | |
| Intercept Pharmaceuticals, INC. | $13.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hydrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.